No Regulatory Exemption for Gene-Edited Products in EU 

The European Court of Justice has decided that organisms made with precision techniques such as CRISPR will be subject to the same rules as transgenic plants or animals.

Written byCatherine Offord
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Crops and other products made using gene-editing techniques should be subject to the same regulatory oversight as organisms developed with other genetic-engineering methods, according to a ruling by the European Court of Justice today (July 25). In a setback for the biotech industry, judges have decided that foods and other products created by tools such as CRISPR must go through safety and labeling checks that were designed for genetically modified organisms (GMOs) created by traditional transgenic approaches.

The decision “would appear to cause all new genome edited organisms to be regulated as if they were derived from classical ‘GM’ or transgenic methods as developed in the 1980s,” Denis Murphy, a professor of biotechnology at the University of South Wales, tells the BBC. He adds that “this will potentially impose highly onerous burdens on the use of genome editing both in agriculture and even in medicine, where the method has recently ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • After undergraduate research with spiders at the University of Oxford and graduate research with ants at Princeton University, Catherine left arthropods and academia to become a science journalist. She has worked in various guises at The Scientist since 2016. As Senior Editor, she wrote articles for the online and print publications, and edited the magazine’s Notebook, Careers, and Bio Business sections. She reports on subjects ranging from cellular and molecular biology to research misconduct and science policy. Find more of her work at her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies